4th Drug Discovery Re-Invented Conference

Memo

The fourth Drug Discovery Re-Invented Meeting brings together experts in medicinal chemistry, structure-based drug design, computational chemistry, emerging drug targets, and novel technology platforms. The meeting is extremely interactive with enthusiastic question and answer sessions following each talk. This meeting remains unique with respect to the breadth of participants and focus on new approaches to discovering drugs. With large pharma reducing investment in internal early stage research, drug pipelines will increasingly be filled by alternative sources. These players include: government, academic labs, non-profits, biotech companies, and pharmaceutical "open innovation" models.



Key Sessions

New Approaches in Biotech, Academia, and Pharma

New Screening Technologies and Drug Targets

Structure, Modeling, and Fragment-based Design

Government and Non-profit Sector in Drug Discovery and Development

Importance of CROs in Supporting the Virtual Drug Discovery Model

Emerging Pharmacological Targets

Industry Exhibit



Scientific chairs: Bill Kinney (Enterin Inc.) and Charles Reynolds (GFree Bio, LLC)



URLs:

Tickets: https://go.evvnt.com/224152-2?pid=5569

Booking: https://go.evvnt.com/224152-3?pid=5569



Time: 14:00 to 12:00



Venue details: Melia Nassau Beach All Inclusive, Nassau West Bay Street, Nassau, Bahamas



Price:

Academic from: USD 1822.0,

Industry from: USD 1822.0,

Student from: USD 1533.0



Speakers: Vicky Steadman (Selcia Ltd), Jay Wrobel (FCCDC), Andrew Cole (Arbutus Bio), Vicki Feher (Schrodinger), Ted Price (CerSci Therapeutics), Christopher Savile (Intrexon), Bart DeCorte (Merachem), Matt Todd (Blumberg Institute)